Key Takeaways
- • US venture-building professional David D'Angelo told Business Recorder Research that Pakistani startups should prioritise customer acquisition and revenue over raising venture capital as their primary objective.
- • D'Angelo, who has worked with hundreds of university-based hard-tech startups from MIT, Stanford, Princeton, Northwestern and Johns Hopkins, says those founders helped secure over $600 million in follow-on funding.
- • D'Angelo cautioned against competing internationally on price alone, warning that a 60% discount signals buyers the product is 60% worse.
- • He identified $10M+ ARR as the milestone at which international venture capital begins paying attention to emerging-market startups.
- • D'Angelo called for government-backed grants to fund capital-intensive deep-tech startups, which need non-dilutive capital before generating revenue.
Summary
D'Angelo argued that bootstrapping is a viable alternative financing model at present, stating that "the best thing a startup can do is drive revenue" and that investment "will follow" once a repeatable model for generating sales opportunities is in place. He said he has worked with hundreds of university-based hard-tech startups affiliated with MIT, Stanford, Princeton, Northwestern and Johns Hopkins, helping founders secure over $600 million in follow-on funding, according to the report.
On international expansion, D'Angelo cautioned Pakistani founders against competing solely on price, warning that low pricing can undermine perceptions of product quality. He also flagged poor market positioning, failure to establish credibility, excessive reliance on cold outreach and slow responses as common mistakes made by emerging-market startups targeting overseas customers. He said Pakistani startups need to build profitable businesses and reach meaningful revenue milestones, such as $10M+ ARR, to shift international investors' perceptions of the market.
D'Angelo also called for government-backed grants to support capital-intensive deep-tech startups, arguing such companies require non-dilutive funding for technology development and commercialisation before generating revenue. He said such grants would need to be complemented by a venture capital ecosystem willing to take risky bets in medtech, agtech, cleantech and other categories historically overlooked because of their capital intensity and risk.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.